Fact-checked by Grok 2 weeks ago

Chlortalidone

Chlortalidone, also known as chlorthalidone, is a thiazide-like diuretic medication that promotes the excretion of sodium and water by the kidneys to treat hypertension and edema.^[1] It belongs to the class of sulfonamide-derived diuretics and was first approved by the FDA in 1960 for these indications.^[2] Chemically, it has the molecular formula C₁₄H₁₁ClN₂O₄S and is available in oral tablet form under brand names such as Hygroton, Thalitone, and HemiClor.^[3]^[4] Chlortalidone works by inhibiting the Na⁺/Cl^- symporter in the distal convoluted tubule of the kidney, which increases urine production and reduces blood volume and pressure.^[1] Its pharmacokinetics include an onset of action within 2-3 hours, peak effects at 2-6 hours, and a prolonged duration of 48-72 hours due to a half-life of 45-60 hours, making it more potent and longer-acting than hydrochlorothiazide.^[1] It is highly protein-bound (about 75%) and primarily excreted unchanged by the kidneys.^[3] Clinically, chlortalidone is indicated as a first-line treatment for hypertension in adults, where it lowers the risk of cardiovascular events like strokes and heart failure, as demonstrated in trials such as ALLHAT.^[1] It is also used adjunctively for edema in conditions including heart failure, hepatic cirrhosis, renal dysfunction, and nephrotic syndrome.^[2] Off-label applications include managing calcium nephrolithiasis, Ménière's disease, and nephrogenic diabetes insipidus.^[1] Typical dosing for hypertension starts at 12.5-25 mg once daily, while for edema it ranges from 50-100 mg daily, with monitoring required for electrolyte imbalances like hypokalemia and hyponatremia. Contraindications include anuria and hypersensitivity to sulfonamides, and common adverse effects encompass dizziness, muscle cramps, and increased uric acid levels potentially leading to gout.^[2]

Medical uses

Hypertension and cardiovascular protection

Chlorthalidone serves as a first-line thiazide-like diuretic for the management of essential hypertension, often used as monotherapy or in combination with other antihypertensive agents.^[1] Recommended doses typically range from 12.5 to 25 mg daily, which effectively lower systolic blood pressure by approximately 10 to 15 mmHg in clinical settings.^[1] This blood pressure reduction is attributed in part to its diuretic mechanism, which promotes natriuresis and decreases plasma volume, contributing to long-term hemodynamic improvements.^[1] Clinical trials have demonstrated chlorthalidone's superiority over hydrochlorothiazide (HCTZ) in blood pressure control and cardiovascular risk reduction. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, 2002), chlorthalidone (12.5–25 mg daily) reduced the incidence of heart failure by 19% compared to lisinopril and by 38% compared to amlodipine, while also lowering stroke risk by 15% relative to lisinopril among high-risk hypertensive patients.^[5] Similarly, the Systolic Hypertension in the Elderly Program (SHEP, 1991) showed that chlorthalidone-based therapy (starting at 12.5 mg daily) reduced total stroke by 36%, ischemic stroke by 37%, and overall cardiovascular events by 32% in older adults with isolated systolic hypertension.^[6] A 2019 meta-analysis further supports chlorthalidone's edge over HCTZ, reporting a greater systolic blood pressure reduction of 3.26 mmHg (95% CI: -4.5 to -2 mmHg) and lower rates of cardiovascular events, positioning it as a preferred option for patients at elevated risk.^[7] More recent evidence from the CLICK trial (2022, with 2024 follow-up analysis) confirms cardiovascular benefits but shows no superiority over HCTZ in preventing chronic kidney disease progression, with a higher risk of hypokalemia associated with chlorthalidone.^[8]^[9] Regarding cardiovascular protection, chlorthalidone promotes regression of left ventricular hypertrophy (LVH), a key target organ damage in hypertension. In the SHEP echocardiographic substudy, chlorthalidone treatment led to a 13% decrease in left ventricular mass index over three years, contrasting with a 6% increase in the placebo group, primarily through sustained blood pressure lowering.^[10] Long-term analyses from the Multiple Risk Factor Intervention Trial indicate that chlorthalidone achieves greater LVH regression than HCTZ, with differences in electrocardiographic measures such as Sokolow-Lyon voltage (-93.9 μV vs. -54.9 μV over 48 months), potentially contributing to reduced mortality via enhanced myocardial effects beyond blood pressure control alone.^[11]

Edema management

Chlorthalidone is indicated as adjunctive therapy for edema associated with congestive heart failure, hepatic cirrhosis, renal dysfunction (including nephrotic syndrome), and the administration of corticosteroids or estrogens.^[2] The typical initial dosage for edema management is 50–100 mg administered orally once daily, with potential titration up to a maximum of 200 mg daily based on clinical response; in some cases, 100 mg every other day may suffice for maintenance after initial decongestion.^[2]^[12] By inhibiting sodium reabsorption in the distal convoluted tubule, chlorthalidone promotes natriuresis and diuresis with a prolonged duration of action extending up to 72 hours after a single dose, which supports its efficacy in sustained fluid removal without frequent dosing.^[1]^[13] In responsive patients with edema, this leads to notable weight reduction, often in the range of 2–5 kg over the initial treatment period, reflecting effective mobilization of retained fluid.^[14] In cases of refractory edema, particularly in heart failure, chlorthalidone or other thiazide-like diuretics may be combined with loop diuretics to enhance natriuresis through sequential blockade along the nephron, more than doubling urinary sodium excretion and promoting further edema resolution.^[15] This approach is recommended in the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure for patients with persistent congestion despite moderate- to high-dose loop diuretic therapy alone, though it should be initiated cautiously due to risks such as electrolyte imbalances.^[14] Patients with heart failure and low ejection fraction require close monitoring for volume depletion during chlorthalidone therapy, including daily weight assessments, electrolyte levels (e.g., sodium, potassium), renal function, and signs of hypoperfusion, to guide dose adjustments and prevent complications like dehydration or worsening renal impairment.^[14]

Nephrolithiasis prevention

Chlorthalidone plays a key role in preventing nephrolithiasis, particularly calcium-based kidney stones, by modifying urinary chemistry to lower the risk of stone formation in susceptible individuals. Through its inhibitory effect on renal calcium reabsorption in the distal convoluted tubule, it decreases urinary calcium excretion by 30–50%, which substantially reduces the supersaturation of urine with calcium oxalate and calcium phosphate, thereby limiting stone formation in patients with hypercalciuria.^[16] Clinical trials have demonstrated the effectiveness of chlorthalidone at doses of 25 mg daily for reducing stone recurrence in patients with idiopathic hypercalciuria. For instance, in studies summarized across treated and untreated cohorts, recurrence rates dropped from approximately 45% without treatment to 23% with thiazide-like diuretics such as chlorthalidone.^[17]^[18] Chlorthalidone is often preferred over hydrochlorothiazide (HCTZ) in guidelines and recent analyses for nephrolithiasis prevention due to its longer half-life and more sustained reduction in urinary calcium excretion.^[19] This prolonged action provides better 24-hour control compared to shorter-acting thiazides like HCTZ.^[20] Appropriate patient selection is crucial, focusing on individuals with a history of recurrent calcium stones and preserved renal function (e.g., estimated glomerular filtration rate >30 mL/min/1.73 m²), where the benefits in mineral balance outweigh potential risks.^[20]

Other indications

Chlorthalidone has been investigated for its role in preventing bone fractures in postmenopausal women with osteoporosis, primarily through its effects on calcium homeostasis. By inhibiting sodium reabsorption in the distal convoluted tubule, it reduces urinary calcium excretion, leading to mild hypercalcemia that stimulates bone formation and decreases resorption. A large randomized trial in older adults, including many postmenopausal participants, found that chlorthalidone at doses of 12.5 to 25 mg daily was associated with a 21% reduction in the risk of hip and pelvic fractures compared to other antihypertensives.^[21] Another placebo-controlled study in postmenopausal women demonstrated significant reductions in annual bone mineral density loss at the hip and spine with similar low doses over 2.6 years on average.^[22] In the treatment of Ménière's disease, chlorthalidone is used off-label to manage vertigo by reducing endolymphatic hydrops through its diuretic action on fluid balance in the inner ear. Clinical observations indicate that periodic or long-term administration provides symptomatic relief in many patients during active disease phases, with doses typically ranging from 25 to 50 mg daily.^[23] A systematic review supports its inclusion as a first-line diuretic option alongside hydrochlorothiazide and acetazolamide for decreasing vertigo attack frequency, though evidence quality remains moderate due to limited randomized trials.^[24] Chlorthalidone serves as an adjunct in managing central diabetes insipidus in infantile cases, particularly when used with desmopressin to enhance free water clearance and reduce polyuria. By inducing mild volume depletion, it paradoxically increases proximal tubule reabsorption of sodium and water, complementing desmopressin's vasopressin-like effects on the collecting ducts. Guidelines for infantile cases recommend combining thiazide-like diuretics such as chlorthalidone with desmopressin and low-solute diets to optimize urine output control.^[25] Chlorthalidone is used off-label in nephrogenic diabetes insipidus to counteract renal resistance to vasopressin by mechanisms of volume depletion and enhanced solute reabsorption, often in combination with other agents like amiloride. Although effective in reducing urine volume by up to 50% in some cases, it lacks FDA approval for this indication and is reserved for refractory scenarios.^[1]^[26]

Adverse effects

Electrolyte and metabolic disturbances

Chlorthalidone, a thiazide-like diuretic, commonly induces hypokalemia due to increased renal potassium excretion, with an incidence of approximately 12.9% in the first year of treatment among high-risk hypertensive patients. Recent analyses (as of 2024) indicate chlorthalidone is associated with a higher incidence of hypokalemia compared to hydrochlorothiazide.^[9] This electrolyte imbalance elevates the risk of cardiac arrhythmias, particularly in patients with preexisting heart conditions, as low serum potassium levels can prolong the QT interval and predispose to ventricular ectopy.^[27] To mitigate this risk, clinical guidelines recommend routine monitoring of serum potassium and co-administration of potassium-sparing diuretics such as amiloride or spironolactone, or potassium supplementation, especially at doses exceeding 12.5 mg daily.^[28] Hyponatremia occurs in about 4.1% of patients treated with chlorthalidone, compared to 1.3% with placebo, primarily through impaired free water excretion in the distal tubule.^[29] Hypercalcemia is another potential disturbance, resulting from reduced urinary calcium excretion, though its incidence is low (less than 1% in large trials) and typically asymptomatic unless underlying hyperparathyroidism is present.^[28] These changes in renal handling of electrolytes necessitate periodic laboratory assessments to prevent symptomatic complications like confusion or muscle cramps. Chlorthalidone elevates serum uric acid levels by decreasing urate clearance, increasing the risk of gout flares, with an incidence of new-onset gout around 2-4% over several years.^[30] Hyperglycemia and impaired glucose tolerance are also observed, with long-term use associated with a 20-30% increased risk of new-onset diabetes mellitus, particularly in patients with prediabetes or metabolic syndrome, due to hypokalemia-mediated insulin resistance and direct pancreatic effects.^[31] Baseline fasting glucose monitoring and lifestyle interventions are advised to manage this metabolic shift.

Dermatological and hypersensitivity reactions

Chlorthalidone, a sulfonamide-derived thiazide-like diuretic, is associated with dermatological adverse effects primarily manifesting as photosensitivity and various hypersensitivity reactions. Photosensitivity occurs rarely, with an estimated incidence of 1 to 100 cases per 100,000 patients treated with thiazide diuretics, including chlorthalidone, and may lead to exaggerated sunburn-like reactions upon exposure to ultraviolet A (UVA) radiation.^[32] Patients experiencing this should be advised to use sun-protective measures, such as broad-spectrum sunscreen, protective clothing, and avoidance of direct sunlight, to mitigate risks.^[32] Hypersensitivity reactions to chlorthalidone are uncommon but can include cutaneous manifestations such as rash and urticaria, reported in 1% to 10% of users.^[33] More severe reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis, are rare, occurring in less than 0.1% of cases, and typically present with blistering, peeling skin, and mucous membrane involvement.^[1] These reactions are linked to the drug's sulfonamide moiety, which can trigger type IV hypersensitivity in susceptible individuals.^[1] Cross-reactivity with other sulfonamide-containing drugs is a theoretical concern due to structural similarities, but clinical evidence indicates a low actual risk, with only isolated case reports documenting reactions such as rash or fixed drug eruptions in patients with prior sulfonamide antibiotic allergies.^[34] For instance, among patients with documented sulfonamide allergies, subsequent exposure to thiazide diuretics like chlorthalidone rarely provokes cross-reactions, estimated at less than 1% based on limited literature.^[34] Rare case reports have described lichenoid eruptions and alopecia associated with chlorthalidone use. One documented instance involved Graham-Little-Piccardi-Lassueur syndrome, characterized by cicatricial scalp alopecia and lichenoid follicular eruptions, which resolved upon drug discontinuation.^[35] These reactions highlight the potential for idiosyncratic dermatological responses, necessitating prompt evaluation and withdrawal of the medication if suspected.^[35]

Other adverse effects

Chlorthalidone can cause various gastrointestinal adverse effects, including nausea, vomiting, and constipation, which occur in approximately 1% to 10% of patients as general gastrointestinal discomfort, with specific symptoms like nausea and vomiting being less common at rates below 0.1%.^[33] These effects are typically mild and may resolve with continued use or dose adjustment.^[1] Orthostatic hypotension and associated dizziness are notable adverse effects of chlorthalidone, particularly during treatment initiation or with higher doses, due to its blood pressure-lowering action and prolonged duration of effect.^[36] These symptoms arise from volume reduction and can increase fall risk, especially in older adults.^[37] Fatigue and muscle cramps are also reported with chlorthalidone use, often attributable to volume depletion from its diuretic properties rather than direct electrolyte shifts.^[1] These complaints contribute to overall patient discomfort and may necessitate monitoring of hydration status.^[38] Rarely, chlorthalidone has been associated with sexual dysfunction, including impotence in men, with studies indicating a higher incidence compared to placebo or other antihypertensives, potentially emerging early in treatment.^[39] This effect is uncommon but can impact quality of life, warranting discussion with healthcare providers.^[40]

Contraindications and precautions

Contraindications may vary by country; the following are based primarily on US FDA guidance, with additional precautions from international sources.^[2]^[41]

Contraindications

Chlorthalidone is absolutely contraindicated in patients with anuria, as the drug relies on renal excretion and urine production for its elimination, leading to potential accumulation and toxicity in the absence of renal function.^[28] It is also contraindicated in individuals with hypersensitivity to chlorthalidone or other sulfonamide-derived drugs, given the potential for severe allergic reactions including anaphylaxis.^[28]

Drug interactions

Chlorthalidone, a thiazide-like diuretic, can interact with various medications, potentially altering its efficacy or increasing the risk of adverse effects, necessitating careful monitoring and dose adjustments.^[2] When combined with angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), or other antihypertensive agents, chlorthalidone may produce additive hypotensive effects, leading to excessive blood pressure reduction. Close monitoring of blood pressure is recommended to avoid symptomatic hypotension.^[2]^[1]^[42] Concomitant use of chlorthalidone with lithium is generally contraindicated due to decreased renal clearance of lithium, which can result in elevated serum lithium levels and serious toxicity, including neurological symptoms such as tremor, confusion, and seizures. If combination therapy is unavoidable, frequent monitoring of serum lithium concentrations and signs of toxicity is essential, with dose adjustments as needed.^[2]^[1]^[12] Chlorthalidone may impair glucose tolerance and elevate blood glucose levels, potentially reducing the efficacy of antidiabetic agents such as insulin or oral hypoglycemics, which could lead to hyperglycemia in diabetic patients. Monitoring of serum glucose levels is advised, and doses of antidiabetic medications may need to be increased to maintain glycemic control.^[2]^[1]^[43] The hypokalemic effect of chlorthalidone increases the risk of digoxin toxicity when used concurrently, as low potassium levels can enhance digoxin's cardiotoxic potential, potentially causing arrhythmias. Regular monitoring of serum potassium and electrocardiographic evaluation are recommended to prevent complications.^[1]^[42]^[43] Nonsteroidal anti-inflammatory drugs (NSAIDs) can diminish the natriuretic and antihypertensive effects of chlorthalidone by inhibiting renal prostaglandin synthesis, which may counteract the diuretic's action. Blood pressure and renal function should be monitored closely during co-administration, with consideration of alternative analgesics if efficacy is compromised.^[42]^[12]^[43]

Use in special populations

Precautions in specific conditions

Use chlorthalidone with caution in patients with severe renal impairment (e.g., creatinine clearance below 30 mL/min), due to heightened risk of azotemia and cumulative effects; monitor renal function closely and consider discontinuation if deterioration occurs.^[2]^[41] In patients with existing hypokalemia, hyponatremia, or other electrolyte imbalances, the drug may worsen these conditions; monitor and correct electrolytes prior to and during therapy.^[2]^[41] Similarly, caution is advised in individuals with symptomatic hyperuricemia or a history of gout, as chlorthalidone can elevate serum uric acid levels and precipitate gouty attacks; monitor uric acid levels in susceptible patients.^[2]^[44] Regarding pregnancy, chlorthalidone may cause fetal harm, including jaundice, thrombocytopenia, hypoglycemia, and electrolyte disturbances due to transplacental passage; it is not recommended, particularly in the first trimester, and should be avoided unless benefits clearly outweigh potential risks. Alternative antihypertensives are preferred for gestational hypertension.^[2]^[45] In elderly patients, chlorthalidone dosing should begin at the lower end of the range, typically 12.5 mg daily, due to age-related declines in renal function and increased susceptibility to adverse effects such as hyponatremia and electrolyte imbalances.^[2]^[1] Clinical studies in older adults have demonstrated a higher incidence of eGFR decline and cardiovascular events with chlorthalidone compared to alternatives like hydrochlorothiazide, emphasizing the need for close monitoring of serum electrolytes and renal function during initiation and titration.^[46] During pregnancy, chlorthalidone is generally avoided unless the potential benefits outweigh the risks, as it crosses the placenta and is associated with fetal or neonatal complications including jaundice, thrombocytopenia, hypoglycemia, and electrolyte disturbances.^[2]^[47] Observational data indicate no substantial increase in major congenital malformations or miscarriage risk, but authorities recommend alternative antihypertensives for gestational hypertension.^[1] In lactation, chlorthalidone is excreted into breast milk, potentially causing dehydration or electrolyte issues in the infant, so its use is discouraged; monitoring for infant effects is essential if administration is unavoidable.^[2]^[38] For patients with renal impairment, chlorthalidone requires caution, particularly when creatinine clearance is below 30 mL/min, where it may precipitate azotemia; dose reductions to 12.5–25 mg daily are advised for CrCl 30–50 mL/min, with regular assessment of renal function to guide adjustments.^[48]^[1] In hepatic impairment, no specific dosage modifications are outlined, but caution is warranted due to potential exacerbation of hepatic encephalopathy from fluid and electrolyte shifts; it should be avoided in decompensated liver disease.^[1] Studies confirm efficacy at standard low doses (e.g., 25 mg) even in moderate renal dysfunction, but cumulative effects necessitate individualized monitoring.^[49] Pediatric use of chlorthalidone is limited by insufficient safety and efficacy data, and it is not routinely recommended except in select cases of edema associated with nephrotic syndrome or hypertension unresponsive to other therapies.^[2] Dosing, when considered, starts at 0.3 mg/kg/day (up to 2 mg/kg/day, not exceeding 50 mg), administered with food to enhance absorption, but long-term outcomes remain understudied, requiring specialist oversight.^[50]^[51]

Pharmacology

Mechanism of action

Chlorthalidone primarily acts as a diuretic by inhibiting the sodium-chloride cotransporter (NCC), also known as the Na⁺/Cl⁻ symporter, located on the apical membrane of epithelial cells in the distal convoluted tubule (DCT) of the nephron. This inhibition prevents the reabsorption of sodium and chloride ions from the tubular lumen, leading to their increased urinary excretion along with osmotically obligated water; this process accounts for approximately 5% of the filtered sodium load under normal conditions.^[52]^[53] In addition to its effects on the NCC, chlorthalidone weakly inhibits carbonic anhydrase isozymes, particularly CA II, due to its sulfonamide group. This inhibition impairs the enzyme's role in facilitating bicarbonate reabsorption in the proximal tubule and DCT, resulting in mild bicarbonate diuresis and a subtle metabolic acidosis that enhances the drug's natriuretic potency.^[54]^[1] Chlorthalidone's antihypertensive effects extend beyond diuresis through direct vasodilatory actions on vascular smooth muscle cells, which occur independently of volume depletion and contribute to reduced peripheral vascular resistance. These effects may involve calcium desensitization in smooth muscle, attenuating agonist-induced vasoconstriction via Rho kinase pathways, as well as decreased vascular permeability and promotion of angiogenesis.^[55]^[56] Over the long term, chlorthalidone sustains blood pressure reduction partly through modulation of renal prostaglandins, including inhibition of PGE₂-9-ketoreductase, which alters prostaglandin metabolism and enhances vasodilation while decreasing vascular resistance.^[57]^[58]

Pharmacokinetics

Chlorthalidone is administered orally and exhibits an absolute bioavailability of approximately 64% following a 50 mg dose.^[41] Peak plasma concentrations are typically reached within 2 to 6 hours after ingestion, with the onset of diuretic effects occurring around 2 to 3 hours post-dose.^[3] The duration of action is prolonged, lasting 24 to 72 hours, which supports once-daily dosing.^[28] The drug is approximately 75% bound to plasma proteins, primarily albumin, with additional high affinity for erythrocyte carbonic anhydrase, contributing to its extended half-life of 40 to 60 hours.^[3] This protein binding and tissue distribution result in a volume of distribution of about 2.4 L/kg, allowing for accumulation in erythrocytes and slow release back into plasma.^[1] Steady-state plasma levels are generally achieved after 2 to 3 weeks of continuous dosing due to the long elimination half-life.^[59] Metabolism of chlorthalidone is minimal and occurs partially in the liver, with no major active metabolites identified.^[3] Elimination is primarily renal, with the major portion of the dose excreted unchanged in the urine via glomerular filtration and active tubular secretion; the remainder is eliminated through non-renal routes.^[28] In patients with renal impairment, the drug accumulates due to reduced clearance, necessitating dose adjustments.^[1]

Chemistry

Structure and physical properties

Chlorthalidone possesses the molecular formula C₁₄H₁₁ClN₂O₄S and a molecular weight of 338.78 g/mol. It is a monosulfamoylbenzamide characterized by a benzene-fused phthalimidine ring system. Although classified as a thiazide-like diuretic, chlorthalidone is structurally distinct from thiazide diuretics, lacking the benzothiadiazine ring, with its pharmacological activity largely stemming from the sulfonamide moiety.^[3]^[60]^[61] The compound manifests as a white to yellowish-white, odorless or nearly odorless crystalline powder. It exhibits a melting point of 215–220 °C (with decomposition). Chlorthalidone is sparingly soluble in water (about 120 mg/L at 25 °C), practically insoluble in ether and chloroform, slightly soluble in ethanol, and freely soluble in methanol and dilute alkaline solutions; its pK_a of 9.4 reflects weak acidic behavior, remaining largely unionized under physiological conditions.^[3]^[60]^[62] Chlorthalidone demonstrates sensitivity to light and is stable when stored in airtight containers at room temperature (below 40 °C), with a typical shelf life of 5 years under these conditions.^[60]

Synthesis

Chlorthalidone was first synthesized through a patented process in 1957, which begins with the condensation of 3-nitro-4-chlorobenzoic acid and phthalide to form the key intermediate 2-(3-nitro-4-chlorobenzoyl)benzoic acid. This intermediate undergoes selective reduction using cuprous chloride and potassium iodide to yield 2-(3-amino-4-chlorobenzoyl)benzoic acid.^[63] Subsequent steps include diazotization of the amino group, followed by sulfonation to introduce the sulfonyl chloride functionality, chlorination to form the phthalide derivative, and finally ammonolysis to produce chlorthalidone.^[64] The industrial production of chlorthalidone follows a multi-step process with overall yields typically around 70%, emphasizing high-purity intermediates to minimize impurities.^[65] Key manufacturing considerations include the use of reversed-phase high-performance liquid chromatography (RP-HPLC) for validation and control of process-related impurities in the active pharmaceutical ingredient (API), ensuring compliance with pharmaceutical standards such as those outlined in the European Pharmacopoeia.^[65] The process avoids hazardous diazotization in some optimized variants by starting from 2-(4-chlorobenzoyl)benzoic acid, followed by reduction, sulfonation with chlorosulfonic acid, and hydroxylation using hydrogen peroxide under basic conditions.^[66] Research has explored variants such as Schiff base derivatives of chlorthalidone, formed by condensation of the sulfonamide group with aldehydes, to potentially enhance biological activity, including as inhibitors of dihydrofolate reductase; however, these modifications do not alter the standard API structure used in clinical formulations.

Society and culture

History

Chlorthalidone was discovered by researchers at Geigy, a Swiss pharmaceutical company now part of Novartis, and was first described in a 1959 publication in Helvetica Chimica Acta.^[3] The compound was patented by Geigy Chemical Corporation with a priority filing date of November 4, 1957, under US Patent 3,055,904, which covered new isoindoline derivatives including chlorthalidone for its diuretic properties.^[64] It was initially developed as part of efforts to create long-acting sulfonamide-based diuretics following the success of earlier thiazides like chlorothiazide. Chlorthalidone was first marketed under the brand name Hygroton in 1960, initially approved in Europe for the treatment of hypertension and edema.^[67] In the United States, the Food and Drug Administration approved chlorthalidone for similar indications in 1960, marking its entry into clinical practice as a thiazide-like diuretic with prolonged action compared to shorter-acting alternatives.^[68] Early adoption focused on its efficacy in managing fluid retention and blood pressure, with Hygroton becoming a standard option in antihypertensive regimens during the 1960s. The cardiovascular benefits of chlorthalidone were solidified through major clinical trials in the late 20th century. The Systolic Hypertension in the Elderly Program (SHEP), published in 1991, demonstrated that low-dose chlorthalidone-based stepped-care therapy reduced the risk of stroke by 36% and overall cardiovascular events by 32% in older adults with isolated systolic hypertension, establishing its role in preventing fatal and nonfatal outcomes.^[69] Similarly, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), reported in 2002, confirmed chlorthalidone's superiority over other agents like lisinopril in reducing stroke, heart failure, and combined cardiovascular events, while highlighting its effectiveness as a first-line diuretic in diverse high-risk populations.^[5] In the 1970s, dose-response studies shifted clinical practice toward lower doses of chlorthalidone to optimize efficacy while minimizing side effects such as hypokalemia. Research, including a 1979 trial, showed that 25 mg daily provided blood pressure reduction comparable to higher doses (50-75 mg) but with significantly less electrolyte disturbance, leading to recommendations for 12.5-25 mg regimens that reduced adverse events without compromising antihypertensive benefits.^[70] This evolution emphasized chlorthalidone's favorable therapeutic index and contributed to its enduring position in hypertension guidelines.

Availability and brand names

Chlorthalidone is widely available as a generic medication in oral tablet formulations, commonly in strengths of 12.5 mg, 25 mg, and 50 mg, with some brands offering 15 mg options.^[71]^[72] It is included on the World Health Organization's Model List of Essential Medicines, having been first added in 2021 for the treatment of essential hypertension and heart failure.^[73] Common brand names for chlorthalidone include Hygroton (manufactured by Novartis), Thalitone, and the low-dose HemiClor (12.5 mg tablets, approved by the FDA on March 17, 2025, for hypertension treatment in adults).^[71]^[74] These formulations are accessible globally through prescription, with generic versions promoting affordability in various healthcare systems. In the United States, chlorthalidone was the 124th most commonly prescribed medication in 2023, accounting for over 5 million prescriptions, reflecting its established role in hypertension management.^[75] Prescription trends for hydrochlorothiazide have declined following 2019 FDA warnings about potential carcinogenic impurities, contributing to greater adoption of chlorthalidone as a preferred thiazide-like diuretic. Chlorthalidone is frequently combined with other agents to enhance efficacy and reduce side effects, such as in fixed-dose products with the beta-blocker atenolol (e.g., Tenoretic) or potassium-sparing diuretics like triamterene or spironolactone to counteract hypokalemia.^[76]^[77] These combination formulations are available in multiple countries and are recommended in guidelines for patients requiring multifaceted antihypertensive therapy.

Regulations and recent developments

Chlorthalidone is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of diuretics and masking agents, banned at all times in competitive sports due to its potential for aiding weight loss, masking the use of other performance-enhancing drugs, or diluting urine samples.^[78]^[79] This prohibition has led to sanctions in various sports, including instances of positive tests in weightlifting and cycling.^[80] In India, chlorthalidone is regulated as a Schedule H drug, requiring a prescription from a registered medical practitioner for sale and dispensing.^[81] Recent research from 2024 and 2025 has further clarified chlorthalidone's comparative efficacy and safety profile relative to hydrochlorothiazide (HCTZ). The CLICK trial, a secondary analysis published in December 2024, evaluated kidney outcomes in patients with hypertension and found that chlorthalidone was not superior to HCTZ in preventing chronic kidney disease progression, end-stage kidney disease, or a ≥30% decline in estimated glomerular filtration rate; however, it was associated with a higher incidence of hypokalemia.^[9] Supporting meta-analyses from this period, including a 2024 review, indicate that chlorthalidone provides superior 24-hour blood pressure control, reducing systolic blood pressure by approximately 3–5 mmHg more than equivalent doses of HCTZ, attributed to its longer duration of action and higher potency.^[82]^[83] A 2025 randomized clinical trial (OPTION TREAT) published in JACC: Advances evaluated a novel triple-combination single-pill formulation containing candesartan cilexetil 16 mg, amlodipine 5 mg, and chlorthalidone 12.5 mg in adults with uncontrolled hypertension despite dual therapy. At 12 weeks, it reduced systolic blood pressure by 22.6 mm Hg (to 128.6 mm Hg) compared to 18.2 mm Hg (to 133.5 mm Hg) with the control combination (valsartan/hydrochlorothiazide/amlodipine), with 69.3% achieving BP <140/90 mm Hg versus 59.8% (P < .001). The trial was conducted in Brazil and suggests potential for improved blood pressure control.^[84]^[85] Prescriptions for thiazide diuretics have declined following 2024 reports and studies highlighting skin cancer risks primarily associated with HCTZ, such as squamous cell carcinoma, prompting a shift toward chlorthalidone, which shows no comparable increased risk in recent analyses, reinforced by the International Agency for Research on Cancer (IARC) classifying hydrochlorothiazide as carcinogenic to humans in November 2024 for causing squamous cell carcinoma of the skin.^[86]^[87]

References

[1]
Chlorthalidone - StatPearls - NCBI Bookshelf - NIH
Chlorthalidone is a thiazide-like diuretic used to treat hypertension. This activity discusses chlorthalidone's indications and contraindications.
[2]
[PDF] Chlorthalidone - accessdata.fda.gov
Chlorthalidone is indicated in adults as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including ...
[3]
Chlorthalidone | C14H11ClN2O4S | CID 2732 - PubChem - NIH
Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or ...
[4]
Major Outcomes in High-Risk Hypertensive Patients Randomized to ...
Dec 18, 2002 · Chlorthalidone was superior to amlodipine (by about 25%) in preventing HF, overall, and for hospitalized or fatal cases, although it did not ...
[5]
Effect of Treating Isolated Systolic Hypertension on the Risk of ...
Jul 26, 2000 · SHEP was a double-blind, randomized, placebo-controlled trial designed to test whether antihypertensive drug therapy reduces the frequency of ...
[6]
Comparative efficacy and safety of chlorthalidone and ... - Nature
Oct 8, 2019 · However, HCTZ seems to be the more commonly used diuretic. Our meta-analysis has demonstrated a slight superiority for CTLD regarding BP control ...
[7]
Effect of Treatment of Isolated Systolic Hypertension on Left ...
This randomized study clearly shows that chlorthalidone therapy is effective in reducing LV mass in elderly patients with isolated systolic hypertension.<|separator|>
[8]
Long-Term Effects of Chlorthalidone Versus Hydrochlorothiazide on ...
Oct 24, 2011 · Our findings on left ventricular hypertrophy support the idea that greater blood pressure reduction with CTD than HCTZ may have led to differences in mortality.
[9]
Thalitone, Hemiclor (chlorthalidone) dosing, indications, interactions ...
Edema. 50-100 mg/day PO or 100 mg PO every other day; not to exceed 200 ... symptoms are noted after 6 hours, discontinue treatment. Dosing Modifications.
[10]
Chlorthalidone Therapy Improves BP Control in Advanced CKD ...
Nov 17, 2021 · “The reported half-life of chlorthalidone is 45 to 60 hours, and the duration of action is even longer at 48 to 72 hours,” the researchers noted ...
[11]
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Apr 1, 2022 · The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
[12]
Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart ...
Oct 26, 2010 · We summarize the existing literature evaluating the combination of loop and thiazide diuretics in patients with heart failure in order to describe the possible ...
[13]
https://www.uspharmacist.com/article/chlorthalidone-therapy-improves-bp-control-in-advanced-ckd-patients
[14]
THIAZIDE DIURETICS FOR STONE PREVENTION
Dec 23, 2015 · Thiazide drugs can reduce stone recurrence at least in part by reducing urine calcium loss and supersaturation. They act on the kidney but also ...Thiazide Type Diuretics... · How Do Thiazides Affect The... · How Do Thiazides Lower Urine...<|control11|><|separator|>
[15]
Chlorthalidone promotes mineral retention in patients with idiopathic ...
Compared to pretreatment, the drugs reduced intestinal calcium absorption; but they reduced urine calcium loss even more, so calcium retention increased.
[16]
Effect of Chlorthalidone and Hydrochlorothiazide on 12-Hour vs 24 ...
Sep 1, 2025 · We conclude that the long-acting and more effective CTD is a preferable agent for stone prevention. Time of administration does not seem to be important.
[17]
Kidney Stones: Medical Mangement Guideline
The purpose of this guideline is to provide a clinical framework for the diagnosis, prevention and follow-up of adult patients with kidney stones.
[18]
Association of 3 Different Antihypertensive Medications With Hip and ...
Nov 21, 2016 · Use of the thiazide-like diuretic chlorthalidone was associated with a 21% significantly lower risk of hip and pelvic fractures compared with either lisinopril ...
[19]
A randomized, double-masked, placebo-controlled trial of ...
Compared with placebo use, chlorthalidone use was associated with significant reductions in annual bone loss rates.
[20]
Diuretic Treatment of Meniere Disease - JAMA Network
Periodic or long-term treatment with chlorthalidone produces a considerable symptomatic relief in many patients during the active stage of the disease.
[21]
A Systematic Review of Diuretics in the Medical Management of ...
Aug 6, 2025 · Diuretics including hydrochlorothiazide, acetazolamide, and chlorthalidone serve as first-line treatments for MD, reducing vertigo attack ...<|control11|><|separator|>
[22]
desmopressin, low renal solute load formula, thiazide diuretics
The management of central diabetes insipidus in infancy: desmopressin, low renal solute load formula, thiazide diuretics. J Pediatr Endocrinol Metab. 2007 ...
[23]
[PDF] Management of Nephrogenic Diabetes Insipidus - Juniper Publishers
Nov 23, 2022 · Treatment strategies include diet restrictions, hydration, thiazide diuretics, indomethacin, chlorthalidone, amiloride, and desmopressin.
[24]
https://www.researchgate.net/publication/296620447_A_Systematic_Review_of_Diuretics_in_the_Medical_Management_of_Menieres_Disease
[25]
Hypokalemia Associated With Diuretic Use and Cardiovascular ...
... clinical trial of chlorthalidone-based treatment of isolated systolic hypertension in older persons. After 1 year of treatment, 7.2% of the participants ...Missing: incidence | Show results with:incidence
[26]
[PDF] THALITONE (chlorthalidone) Tablets USP 15 mg and 25 mg ...
CLINICAL PHARMACOLOGY. Chlorthalidone is a long-acting oral diuretic with antihypertensive activity. Its diuretic action commences a mean of 2.6 hours after ...
[27]
The Silent Epidemic of Thiazide‐Induced Hyponatremia - Mann - 2008
Jun 28, 2008 · ... hyponatremia (defined as a sodium level <130 mEq/L) was observed in 4.1% of patients treated with chlorthalidone vs 1.3% in the control ...
[28]
Comparison of New‐Onset Gout in Adults Prescribed Chlorthalidone ...
Patients prescribed CTD for hypertension have a similar risk of developing new‐onset gout compared with patients prescribed similar doses of HCTZ.
[29]
Antihypertensive Therapy and the Risk of New-Onset Diabetes
May 1, 2006 · These aforementioned observations are evident in 11 randomized clinical outcome trials where development of new-onset diabetes was evaluated as ...
[30]
Drug-Induced Photosensitivity—From Light and Chemistry to ...
It is estimated that between 1 and 100 per 100,000 patients treated with thiazide diuretics exhibit photosensitivity [95,96]. The thiazide class includes, e.g., ...
[31]
Chlorthalidone Side Effects: Common, Severe, Long Term - Drugs.com
Feb 12, 2024 · Chlorthalidone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
[32]
Cross-Reactivity Between Sulfonamides and Loop or Thiazide ... - NIH
It has long been taught that loop and thiazide diuretics pose a theoretical risk of cross sensitivity in a patient with allergy to sulfonamide antimicrobials ...
[33]
GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME IN ... - PubMed
The condition is characterized by the triad of cicatricial scalp alopecia, noncicatricial alopecia in the axillary and groin … ... chlorthalidone, was ...<|separator|>
[34]
Chlorthalidone side effects and how to avoid them - SingleCare
Nov 4, 2022 · The most common side effect of chlorthalidone is electrolyte imbalances, which are changes in the levels of potassium and sodium.<|separator|>
[35]
https://pubmed.ncbi.nlm.nih.gov/40007390/
[36]
Thalitone, Hemiclor (Chlorthalidone): Side Effects, Uses ... - RxList
muscle cramps,; weakness,; fast or irregular heartbeat ... volume depletion may be at particular risk of developing acute renal failure on Chlorthalidone.Missing: fatigue | Show results with:fatigue<|control11|><|separator|>
[37]
Long-term effects on sexual function of five antihypertensive drugs ...
Long-term incidence of erection problems in treated hypertensive men is relatively low but is higher with chlorthalidone treatment.
[38]
Long-term Effects on Sexual Function of Five Antihypertensive ...
The incidence of erection dysfunction with chlorthalidone appeared relatively early (first year) and was unlikely to occur after 2 years.
[39]
[PDF] Chlorthalidone Tablets - [Product Monograph Template - Standard]
Mar 14, 2023 · Patients with anuria, severe renal failure (creatinine clearance lower than 30 mL/min), severe hepatic failure, refractory hypokalemia or ...Missing: CrCl | Show results with:CrCl
[40]
[PDF] Hygroton 25 mg tablets - NEW ZEALAND DATA SHEET
4.3 Contraindications. • Anuria, severe renal failure (creatinine clearance lower than 30 mL/min), and severe hepatic failure. • Hypersensitivity to ...
[41]
[PDF] PrJAMP Chlorthalidone
Dec 23, 2021 · The use of chlorthalidone for other indications (e.g., heart disease) in pregnancy should be avoided, particularly in the first trimester, ...
[42]
Chlorthalidone Interactions - Drugs.com
There are 486 drugs known to interact with chlorthalidone, along with 11 disease interactions, and 2 alcohol/food interactions. Of the total drug interactions, ...
[43]
Chlorthalidone (oral route) - Side effects & dosage - Mayo Clinic
Chlorthalidone is a diuretic (water pill). It reduces the amount of water in the body by increasing the flow of urine, which helps to lower blood pressure.Missing: line | Show results with:line
[44]
Comparison of Clinical Outcomes and Safety Associated ... - PubMed
Sep 1, 2021 · This cohort study found that among older adults, chlorthalidone use was associated with a higher risk of eGFR decline, cardiovascular events ...
[45]
Chlorthalidone Use During Pregnancy - Drugs.com
Oct 7, 2025 · Chlorthalidone Pregnancy Warnings: Use should be avoided; per some authorities, use is contraindicated for hypertension during pregnancy.
[46]
CHLORTHALIDONE - DailyMed
Chlorthalidone should be used with caution in severe renal disease. In patients with renal disease, chlorthalidone or related drugs may precipitate azotemia.
[47]
Parallel-Group 8-Week Study on Chlorthalidone Effects in ...
Jan 6, 2014 · The week-8 decrease in weight was 4× greater in patients of the <60group with baseline edema than in patients of the <60group without baseline ...Missing: loss | Show results with:loss
[48]
chlorthalidone: Dosing, contraindications, side effects, and pill pictures
Start: 0.3 mg/kg/dose PO qam; Max: 2 mg/kg/day up to 50 mg/day; Info: give w/ food. renal dosing. [not defined]: renal impairment: consider adult renal dosing ...
[49]
Oral Thiazide Diuretics for Hypertension in Children - Merck Manuals
Because chlorthalidone has a longer duration of action, it may be best for chronic hypertension where a single daily dose may help with adherence.
[50]
Thiazide Diuretics - StatPearls - NCBI Bookshelf - NIH
Jul 6, 2025 · Thiazide diuretics are an FDA-approved class of medications used primarily to manage hypertension and edema by inhibiting sodium reabsorption.Missing: Chlortalidone | Show results with:Chlortalidone
[51]
Revisiting diuretic choice in CKD - PMC - NIH
Furthermore, because the distal tubule is responsible for reabsorbing approximately 5% of the filtered sodium load, there was theoretical concern that thiazide ...
[52]
Carbonic Anhydrase Inhibitors. Comparison of Chlorthalidone and ...
Dec 30, 2008 · Chlorthalidone being 18.3 times more potent against CA II and 150 times more potent against CA I, as compared to indapamide.Introduction · Results and Discussion · Conclusions · References
[53]
Thiazide-like diuretics attenuate agonist-induced vasoconstriction by ...
The study indicates that thiazide-like diuretics inhibit agonist-induced vasoconstriction by calcium desensitization in smooth muscle cells linked to the Rho- ...Missing: sensitizing | Show results with:sensitizing
[54]
Chlorthalidone Decreases Platelet Aggregation and Vascular ...
Jul 12, 2010 · Chlorthalidone and bendroflumethiazide reduced vascular permeability to albumin, but only chlorthalidone increased angiogenesis. Thiazides and ...
[55]
mechanisms of action and effect on cardiovascular events - PubMed
The mechanism by which CTDN lowers BP is unclear but may include alterations in whole body regulation and vasodilatory actions on vasculature, possibly mediated ...
[56]
Inhibition of renal PGE2-9-ketoreductase by diuretics - ScienceDirect
Some inhibition of PGE2-9-ketoreductase was also observed with chlorthalidone ... renal consequences of inhibiting prostaglandin biosynthesis. Increase of ...
[57]
Thiazide diuretics are back in CKD: the case of chlorthalidone - PMC
Due to reduced proximal sodium reabsorption, distal sodium delivery is augmented in CKD, which triggers a 4- to 5-fold increase in distal sodium reabsorption [5] ...Missing: percentage | Show results with:percentage
[58]
Chlorthalidone (PIM 126) - INCHEM
PHYSICO-CHEMICAL PROPERTIES. 3.1 Origin of the substance. 3.2 Chemical structure. 3.3 Physical properties ... Molecular weight: 338.78 3.3 Physical properties ...Missing: formula | Show results with:formula
[59]
Chlorthalidone: Uses, Interactions, Mechanism of Action - DrugBank
Chlorthalidone is a diuretic used to treat hypertension or edema caused by heart failure, renal failure, hepatic cirrhosis, estrogen therapy, and other ...Identification · Pharmacology · Products · References
[60]
Tailoring Chlorthalidone Aqueous Solubility by Cocrystallization
With a pKa of 9.36 [10], CTD is a weak acid and essentially non-ionized in the pH range encompassing the gastrointestinal tract (pH 1–7). In addition to the ...
[61]
Synthesis method of chlorthalidone medicine intermediate 2-(3 ...
The method comprises the following steps: reacting 2-(3-nitro-4-chlorobenzoyl)benzoic acid with cuprous chloride and potassium iodide, washing the obtained ...Missing: phthalide | Show results with:phthalide
[62]
US3055904A - New isoindoline derivatives - Google Patents
1961-02-17. Application filed by Geigy Chemical Corp. 1962-09-25. Application granted. 1962-09-25. Publication of US3055904A. 1979-09-25. Anticipated expiration.
[63]
Improved process for the preparation of chlorthalidone
The present invention provides an improved process that is industrially viable for the preparation of chlorthalidone, as summarized in scheme 1 below.
[64]
Synthesis and Pharmacology of Clinical Drugs Containing ... - MDPI
The synthetic method for accessing chlorthalidone (VII) was first described by Graf and co-workers [54]. A number of patents also describe the synthesis of VII ...<|control11|><|separator|>
[65]
HemiClor (chlorthalidone) FDA Approval History - Drugs.com
May 6, 2025 · ... first approved in 1960 under the brand name Hygroton. Hygroton tablets were originally approved in 25 mg and 50 mg strengths, and although ...Missing: marketed | Show results with:marketed
[66]
Spironolactone and chlorthalidone—old drugs, new uses—but ... - NIH
Chlorthalidone was approved by the US Food and Drug Administration (FDA) in 1960. In 2021, chlorthalidone was shown to be effective for the treatment of ...Missing: 1965 | Show results with:1965
[67]
Prevention of stroke by antihypertensive drug treatment in ... - PubMed
Antihypertensive stepped-care drug treatment with low-dose chlorthalidone as step 1 medication reduced the incidence of total stroke by 36%.
[68]
Dose response to chlorthalidone in patients with mild hypertension ...
We conclude that chlorthalidone, 25 mg daily, was at least as effective for hypertension as 50 and 75 mg with less perturbation of potassium.Missing: 1970s | Show results with:1970s
[69]
Chlorthalidone - brand name list from Drugs.com
Products containing chlorthalidone: chlorthalidone systemic. Brand names: Hygroton, Thalitone, Hemiclor. Drug class: thiazide diuretics.Missing: formulations | Show results with:formulations
[70]
Chlorthalidone (Hemiclor, Hygroton, and others): Uses, Side Effects ...
May 30, 2024 · Chlorthalidone is a diuretic, also called a water pill, that may be used to reduce edema (fluid retention) caused by the following ...
[71]
Chlortalidone - eEML - Electronic Essential Medicines List
First added in 2021 (TRS 1035) for Essential hypertension. Changed in 2021 (TRS 1035) for Heart failure. Therapeutic equivalent for.
[72]
[PDF] NDA 218647 NDA APPROVAL PRM Pharma, LLC c/o RiconPharma ...
Mar 17, 2025 · This NDA provides for the use of Hemiclor (chlorthalidone) tablets for the treatment of hypertension in adults, to lower blood pressure.
[73]
The Top 300 of 2023 - ClinCalc
Aug 10, 2025 · Total Prescriptions (2023), Total Patients (2023), Annual Change. 1 ... Chlorthalidone, 5,041,667, 1,459,485, 16. 125, Isosorbide, 5,038,468 ...The Top 200 of 2023 · Atorvastatin · Metformin · Lisinopril
[74]
[PDF] TENORETIC® (atenolol and chlorthalidone) - accessdata.fda.gov
TENORETIC® (atenolol and chlorthalidone) is for the treatment of hypertension. It combines the antihypertensive activity of two agents: a beta1-selective ( ...Missing: Chlortalidone | Show results with:Chlortalidone
[75]
Combination Antihypertensive Drugs: Recommendations for Use
May 15, 2000 · Atenolol and chlorthalidone (50 mg ... Fixed-dose potassium-sparing–thiazide diuretic combinations have been in use for more than 20 years.
[76]
The Prohibited List | World Anti Doping Agency - WADA
Jun 1, 2019 · The List of Prohibited Substances and Methods (List) indicates what substances and methods are prohibited in sport and when.Athletes & Support Personnel · Liste des interdictions · Footer
[77]
Elimination profile of low‐dose chlortalidone and its detection in hair ...
Feb 19, 2024 · Although diuretics and masking agents are prohibited by the World Anti-Doping Agency (WADA) at all times in sports, substances belonging to this ...
[78]
Sanctions - Anti-Doping Violations - USADA
Sanctions & Prohibited Association ; Park, Mariah, Weightlifting, Chlorthalidone ; Frey, John, Cycling, Non-Analytical: Refusal to Submit to Sample Collection ...
[79]
Chlorthalidone : Indications, Uses, Dosage, Drugs Interactions, Side ...
Sep 10, 2022 · Medicine Type : Allopathy ; Prescription Type: Prescription Required ; Approval : DCGI (Drugs Controller General of India) ; Schedule Schedule H.Missing: regulations | Show results with:regulations
[80]
Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in ...
Dec 10, 2024 · Many clinical trials evaluating cardiovascular outcomes have found that chlorthalidone is beneficial. Several observational studies ...
[81]
Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment ...
May 14, 2024 · Previous research has indicated that CTD may offer better 24-hour BP control than HCTZ, potentially leading to more significant cardiovascular benefits.Missing: essential | Show results with:essential<|separator|>
[82]
The Distal Convoluted Tubule Showdown: Chlorthalidone versus ...
Feb 7, 2023 · Patients on chlorthalidone had more monitoring for hypokalemia, and incidence of hospitalizations for hypokalemia was higher in the ...
[83]
Efficacy and Safety of a Novel Triple Single-Pill for Uncontrolled ...
Conclusions. A novel triple-pill containing candesartan cilexetil, amlodipine, and chlorthalidone improved BP control at 12 weeks and had a reasonable safety ...
[84]
https://www.jacc.org/doi/10.1016/j.jacadv.2025.102175
[85]
Use of Hydrochlorothiazide in the United States Following Label ...
Oct 13, 2024 · Studies have consistently linked HCTZ use to a heightened risk of non-melanoma skin cancer (NMSC) [3-6], a risk not officially recognized with ...